Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Edit custom filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2002 1
2005 1
2006 1
2007 1
2008 3
2009 2
2010 1
2011 3
2012 2
2013 1
2014 3
2015 4
2016 6
2017 6
2018 5
2019 14
2020 31
2021 49
2022 55
2023 32
2024 47
2025 39
2026 8

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

277 results

Results by year

Filters applied: . Clear all
Page 1
Efficacy and Safety of Baxdrostat in Uncontrolled and Resistant Hypertension.
Flack JM, Azizi M, Brown JM, Dwyer JP, Fronczek J, Jones ESW, Olsson DS, Perl S, Shibata H, Wang JG, Wilderäng U, Wittes J, Williams B; BaxHTN Investigators. Flack JM, et al. N Engl J Med. 2025 Oct 9;393(14):1363-1374. doi: 10.1056/NEJMoa2507109. Epub 2025 Aug 30. N Engl J Med. 2025. PMID: 40888730 Free PMC article. Clinical Trial.
Viral Myocarditis: Classification, Diagnosis, and Clinical Implications.
Sozzi FB, Gherbesi E, Faggiano A, Gnan E, Maruccio A, Schiavone M, Iacuzio L, Carugo S. Sozzi FB, et al. Among authors: carugo s. Front Cardiovasc Med. 2022 Jun 20;9:908663. doi: 10.3389/fcvm.2022.908663. eCollection 2022. Front Cardiovasc Med. 2022. PMID: 35795363 Free PMC article. Review.
Real-World Efficacy and Safety of Inclisiran: A Single-Country, Multicenter, Observational Study (CHOLINET Registry).
Gargiulo P, Marzano F, Crisci M, Marcucci R, Bruzzese D, Maloberti A, Sarullo FM, Galasso G, Indolfi C, Musumeci G, Corleto A, Calabrò P, Carugo S, Casu G, Picciolo A, Ciccone MM, Bilato C, Polimeni A, Giallauria F, Catalano A, De Luca L, Niccoli G, Venturini E, Pepe M, Montisci R, Brunetti ND, Patti G, Porto I, Margonato A, Floresta M, Muscoli S, Cameli M, Andò G, Di Lorenzo E, Berteotti M, Giannattasio C, Sarullo S, Formisano C, Di Costanzo A, Delnevo F, Varbella F, Cesaro A, Franzese M, Mancusi C, Fontanarosa S, Di Santo M, Cotticelli C, Perrone Filardi F, Paolillo S, Esposito G, Corsini A, Perrone Filardi P; CHOLINET Investigators. Gargiulo P, et al. Among authors: carugo s. J Am Coll Cardiol. 2025 Feb 11;85(5):536-540. doi: 10.1016/j.jacc.2024.10.106. Epub 2024 Dec 11. J Am Coll Cardiol. 2025. PMID: 39665700 Free article. No abstract available.
Vericiguat in patients with chronic heart failure and reduced ejection fraction (VICTOR): a double-blind, placebo-controlled, randomised, phase 3 trial.
Butler J, McMullan CJ, Anstrom KJ, Barash I, Bonaca MP, Borentain M, Corda S, Ezekowitz JA, Felker GM, Gates D, Lam CSP, Lewis EF, Lindenfeld J, Mentz RJ, O'Connor CM, Ponikowski P, Reddy YNV, Rosano GMC, Saldarriaga C, Senni M, She L, Teixeira PP, Udelson J, Urbinati A, Vlajnic V, Voors AA, Xing A, Patel MJ, Zannad F; VICTOR Study Group. Butler J, et al. Lancet. 2025 Sep 27;406(10510):1341-1350. doi: 10.1016/S0140-6736(25)01665-4. Epub 2025 Aug 30. Lancet. 2025. PMID: 40897189 Clinical Trial.
Sweeteners: erythritol, xylitol and cardiovascular risk-friend or foe?
Wölnerhanssen BK, Meyer-Gerspach AC, Arduini A, D'Alessandro A, Gronda E, Carugo S, Bonomini M, Gallieni M, Masola V, Angelillo-Scherrer A, Prosdocimi T, Lopaschuk GD. Wölnerhanssen BK, et al. Among authors: carugo s. Cardiovasc Res. 2025 Aug 14;121(9):1319-1329. doi: 10.1093/cvr/cvaf091. Cardiovasc Res. 2025. PMID: 40444390 Free PMC article. Review.
Initiation of sacubitril/valsartan in haemodynamically stabilised heart failure patients in hospital or early after discharge: primary results of the randomised TRANSITION study.
Wachter R, Senni M, Belohlavek J, Straburzynska-Migaj E, Witte KK, Kobalava Z, Fonseca C, Goncalvesova E, Cavusoglu Y, Fernandez A, Chaaban S, Bøhmer E, Pouleur AC, Mueller C, Tribouilloy C, Lonn E, A L Buraiki J, Gniot J, Mozheiko M, Lelonek M, Noè A, Schwende H, Bao W, Butylin D, Pascual-Figal D; TRANSITION Investigators. Wachter R, et al. Eur J Heart Fail. 2019 Aug;21(8):998-1007. doi: 10.1002/ejhf.1498. Epub 2019 May 27. Eur J Heart Fail. 2019. PMID: 31134724 Free article. Clinical Trial.
Vericiguat for patients with heart failure and reduced ejection fraction across the risk spectrum: an individual participant data analysis of the VICTORIA and VICTOR trials.
Zannad F, O'Connor CM, Butler J, McMullan CJ, Anstrom KJ, Barash I, Bonaca MP, Borentain M, Corda S, Gates D, Ezekowitz JA, Hernandez AF, Lam CSP, Lewis EF, Lindenfeld J, Mentz RJ, Ponikowski P, Reddy YNV, Rosano GMC, Saldarriaga C, Senni M, Teixeira PP, Udelson J, Urbinati A, Vlajnic V, Voors AA, Xing A, Patel MJ, Armstrong PW; VICTORIA and VICTOR Study Groups. Zannad F, et al. Lancet. 2025 Sep 27;406(10510):1351-1362. doi: 10.1016/S0140-6736(25)01682-4. Epub 2025 Aug 30. Lancet. 2025. PMID: 40897188 Free article. Clinical Trial.
277 results